

Check Form for Errors

Save

Study Record: PHS Human Subjects and Clinical Trials Information

OMB Number: 0925-0001

Expiration Date: 02/28/2023

* Always required field

Section 1 - Basic Information

1.1. * Study Title (each study title must be unique)

This should match the title on your application.

1.2. * Is this Study Exempt from Federal Regulations?

Yes No

1.3. Exemption Number

1 2 3 4 5 6 7 8

1.4. * Clinical Trial Questionnaire

If the answers to all four questions below are yes, this study meets the definition of a Clinical Trial.

1.4.a. Does the study involve human participants?

Yes No

1.4.b. Are the participants prospectively assigned to an intervention?

Yes No

1.4.c. Is the study designed to evaluate the effect of the intervention on the participants?

Yes No

1.4.d. Is the effect that will be evaluated a health-related biomedical or behavioral outcome?

Yes No

1.5. Provide the ClinicalTrials.gov Identifier (e.g., NCT87654321) for this trial, if applicable

Section 2 - Study Population Characteristics

Section 2 is required for all Human Subjects Research. Please complete all fields.

2.1. Conditions or Focus of Study

At least 1 entry is *required*, and up to 20 entries are allowed (enter each entry on its own line). Each entry is limited to 225 characters.

Identify the name(s) of the disease(s) or condition(s) you are studying, or the focus of the study. If available, use appropriate descriptors from NLM's Medical Subjects Headings (MeSH) so the application can be categorized: <https://meshb.nlm.nih.gov/search>

2.2. Eligibility Criteria

List the study's inclusion and exclusion criteria. To provide a bulleted list, use a dash (or other character) followed by a space ("- ") at the start of each bullet. Be sure to check the format in the assembled application image. Further explanation or justification should be included in attachment [2.5 Recruitment and Retention Plan](#). Your text entry is limited to 15,000 characters (but typically needs only ~500 characters).

2.3. Age Limits

Minimum Age

Maximum Age

Years

2.3.a. Inclusion of Individuals Across the Lifespan

Add Attachment

Delete Attachment

View Attachment

2.4. Inclusion of Women and Minorities

Add Attachment

Delete Attachment

View Attachment

2.5. Recruitment and Retention Plan

This is required unless you selected *only Exemption 4* for question "1.3 Exemption Number."

Add Attachment

Delete Attachment

View Attachment

2.6. Recruitment Status

2.7. Study Timeline

Add Attachment

Delete Attachment

View Attachment

2.8. Enrollment of First Participant

Do not complete this field if you are using an existing dataset or resource.

This is otherwise required unless you selected *only Exemption 4* for question "1.3 Exemption Number."

2.9. Inclusion Enrollment Report(s)

Add Inclusion Enrollment Report

An Inclusion Enrollment Report is required for all human subjects studies unless, on question "1.3 Exemption Number," you selected *only Exemption 4* and no other exemptions.

Each proposed study otherwise *must* contain at least one Inclusion Enrollment Report (IER). However, more than one IER per study is allowed (for example, Aim 1 includes focus group or interviews and Aim 2 includes a device study). Select "Add Inclusion Enrollment Report" to add a new IER.

Section 3 - Protection and Monitoring Plans

Section 3 is required for all Human Subjects Research. Please complete all fields.

3.1. Protection of Human Subjects

Add Attachment

Delete Attachment

View Attachment

3.2. Is this a multi-site study that will use the same protocol to conduct non-exempt human subjects research at more than one domestic site?

Yes No N/A

If yes, describe the single IRB plan

This attachment is **not** required.

Add Attachment

Delete Attachment

View Attachment

3.3. Data and Safety Monitoring Plan

This attachment is *only* required if you answered "Yes" to all 4 questions in Section "1.4 Clinical Trial Questionnaire."

Add Attachment

Delete Attachment

View Attachment

3.4. Will a Data and Safety Monitoring Board be appointed for this study?

Yes No

If you answered "Yes" to all 4 questions in Section "1.4 Clinical Trial Questionnaire" please contact Jason Molony (jmolony@umass.edu) to determine safety oversight. Otherwise, select "No."

3.5. Overall Structure of the Study Team

This attachment is *only* required if you answered "Yes" to all 4 questions in Section "1.4 Clinical Trial Questionnaire."

Add Attachment

Delete Attachment

View Attachment

Section 4 - Protocol Synopsis

4.1. Study Design

4.1.a. Detailed Description

4.1.b. Primary Purpose

4.1.c. Interventions

Intervention Type	
Name	
Description	

4.1.d. Study Phase

Is this an NIH-defined Phase III clinical trial? Yes No

4.1.e. Intervention Model

4.1.f. Masking

Yes No
 Participant Care Provider Investigator Outcomes Assessor

4.1.g. Allocation

4.2. Outcome Measures

Name	
Type	
Time Frame	
Brief Description	

4.3. Statistical Design and Power

Add Attachment

Delete Attachment

View Attachment

4.4. Subject Participation Duration

4.5. Will the study use an FDA-regulated intervention?

Yes

No

4.5.a. If yes, describe the availability of Investigational Product (IP) and Investigational New Drug (IND)/Investigational Device Exemption (IDE) status

Add Attachment

Delete Attachment

View Attachment

4.6. Is this an applicable clinical trial under FDAAA?

Yes

No

4.7. Dissemination Plan

Add Attachment

Delete Attachment

View Attachment

Section 5 - Other Clinical Trial-related Attachments

5.1. Other Clinical Trial-related Attachments

Add Attachments

Delete Attachments

View Attachments